Ascletis Pharma Inc. filed a Next Day Disclosure Return on 3 June 2026, detailing an on-market repurchase of 200,000 ordinary shares conducted the same day. The shares were bought at prices ranging from HK$9.82 to HK$10.25, for a total consideration of HK$2.01 million. All shares acquired are designated for cancellation.

Following the transaction, Ascletis’ share capital structure remains:

• Issued shares (excluding treasury): 1,061.37 million • Treasury shares: 7.08 million • Total issued shares: 1.06846 billion

The opening and closing balances on 2–3 June 2026 are unchanged because the newly repurchased shares have not yet been cancelled.

Repurchases since the current mandate was approved on 22 May 2025 now total 6.69 million shares, representing 0.69% of the company’s issued share base on the mandate date. Of this figure, 6.19 million shares (acquired between 3 April 2025 and 3 June 2026) are still pending cancellation.

Under Hong Kong listing rules, Ascletis is subject to a 30-day moratorium on issuing new shares after the latest buyback, expiring on 3 July 2026.